Altre lingue Champions Oncology, Inc.

Azioni

CSBR

US15870P3073

Mercato chiuso - Nasdaq Altri mercati azionari 21:46:15 09/07/2024			Variaz. 5gg	Var. 1 gen.
5,01 ^USD	-0,20%		+3,09%	-10,85%

04/06	Champions Oncology, Inc. e Medicines Discovery Catapult stringono una partnership per accelerare lo sviluppo di terapie radiofarmaceutiche	CI
13/03	CHAMPIONS ONCOLOGY, INC. : Craig-Hallum dà una valutazione Neutrale	ZM

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Champions Oncology, Inc and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development	04/06
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	15/03
Champions Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	12/03
Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation	08/03
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	13/12
Champions Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	12/12
MORNING BID AMERICAS-Disinflation station	12/12
North American Morning Briefing : Traders Eye -2-	12/12
Champions Oncology, Inc: Champions Oncology erhält für seinen europäischen Forschungsstandort eine ISO-9001:2015-Akkreditierung und ATS-Zertifizierung	02/11
Champions Oncology, Inc.	02/11
Champions Oncology Announces the Addition of Brady Davis as President	18/10/23
Champions Oncology, Inc. Appoints Brady Davis as President	17/10/23
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	13/09/23
Champions Oncology : Reports Quarterly Revenue of $12.6 Million - Form 8-K	13/09/23
Champions Oncology, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	13/09/23
Champions Oncology Announces a Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies	02/08/23
Champions Oncology Enters Multiyear Deal With BioVolume to Better Evaluate Cancer Studies	01/08/23
Champions Oncology, Inc. Announces Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies	01/08/23
Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	24/07/23
Champions Oncology, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	24/07/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Champions Oncology, Inc.

Azioni

CSBR

US15870P3073

Altre lingue

Filtri